Literature DB >> 17240159

Preference for palatable food is reduced by the gamma-hydroxybutyrate analogue GET73, in rats.

Alessandra Ottani1, Sheila Leone, Francisca Belen Garcia Vergara, Raffaella Tacchi, Antonella Loche, Alfio Bertolini.   

Abstract

Palatability and variety of foods are major reasons for "hedonic" eating, and hence for overeating and obesity. Palatable food and drugs of abuse share a common reward mechanism, and compounds that block the reinforcing effect of drugs of abuse preferentially suppress the intake of palatable foods. This research was aimed at studying the influence of the gamma-hydroxybutyrate analogue N-(4-trifluoromethylbenzyl)-4-methoxybutanamide (GET73) - that inhibits alcohol consumption - on consumption and reinforcing effect of palatable food. Adult male rats were used. For place preference conditioning, sweetened corn flakes were used as the reinforcer, and GET73 (50, 100 and 200mgkg(-1)) or vehicle were orally (p.o.) administered either 30min before each training session and the test session, or only before the test session. To study the influence on consumption, GET73 was given p.o. at the same doses once daily for 12 days to rats given free access to both palatable and varied food (cafeteria diet) or to standard chow. Both acquisition and expression of palatable food-induced conditioned place preference were inhibited by GET73, either administered throughout the conditioning period or only before the test session. GET73 reduced also the consumption of cafeteria food, while that of standard chow was increased. At these doses, GET73 had no detrimental effect on open-field behaviour. GET73 seems to specifically attenuate the gratification produced by varied and palatable food, without affecting the consumption of not particularly palatable chow. Since, overweight and obesity are mostly due to the overeating of palatable and varied foods, drugs like GET73 could represent a somewhat ideal and rational approach to obesity treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17240159     DOI: 10.1016/j.phrs.2006.12.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Victoria M Long; Harrison H Tran; Antonella Loche; Roberto Cacciaglia; Robert M Swift; Lorenzo Leggio
Journal:  Eur J Pharm Sci       Date:  2017-08-01       Impact factor: 4.384

2.  The endocannabinoid system modulates the valence of the emotion associated to food ingestion.

Authors:  Mónica Méndez-Díaz; Pavel Ernesto Rueda-Orozco; Alejandra Evelyn Ruiz-Contreras; Oscar Prospéro-García
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

3.  Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Antonella Loche; Victoria M Long; Carla Lobina; Harrison H Tran; Roberto Cacciaglia; Robert M Swift; Giancarlo Colombo; Lorenzo Leggio
Journal:  J Psychopharmacol       Date:  2018-01-23       Impact factor: 4.153

4.  Anti-Alcohol and Anxiolytic Properties of a New Chemical Entity, GET73.

Authors:  Antonella Loche; Francesco Simonetti; Carla Lobina; Mauro A M Carai; Giancarlo Colombo; M Paola Castelli; Domenico Barone; Roberto Cacciaglia
Journal:  Front Psychiatry       Date:  2012-02-14       Impact factor: 4.157

Review 5.  Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Authors:  Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller
Journal:  Front Psychiatry       Date:  2017-08-18       Impact factor: 4.157

Review 6.  Recent Advances in the Modulation of Pain by the Metabotropic Glutamate Receptors.

Authors:  Mariacristina Mazzitelli; Peyton Presto; Nico Antenucci; Shakira Meltan; Volker Neugebauer
Journal:  Cells       Date:  2022-08-21       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.